Ran Hong1, Sung-Chul Lim. 1. Department of Pathology and Research Center for Resistant cells, Medical School, Chosun University, Gwangju 501-140, South Korea.
Abstract
AIM: To evaluate the correlation between the level of (18)F-fluoro-2-deoxyglucose ((18)F-FDG) uptake and glucose transporter 1 (GLUT1) expression in colorectal adenocarcinoma (CRA). METHODS: Forty four patients with resected CRA and preoperative (18)F-FDG positron emission tomography - computed tomography data were investigated in this study. Comparison of maximum standardized uptake value (SUVmax) of the lesion was made with GLUT1 expression by immunohistochemistry and various clinicopathologic factors including tumor volume, invasion depth, gross finding, and lymph node metastasis. RESULTS: SUVmax was 14.45 ± 7.0 in negative GLUT1 expression cases, 15.51 ± 5.7 in weak GLUT1 expression cases, and 16.52 ± 6.8 in strong GLUT1 expression cases, and there was no correlation between between GLUT1 expression and SUVmax. SUVmax was significantly correlated with tumor volume (P < 0.001). However, there was no significant differences in SUVmax and GLUT1 expression among other clinicopathologic factors. CONCLUSION: GLUT1 expression does not correlates significantly with (18)F-FDG uptake in CRA. (18)F-FDG uptake was increased with tumor volume, which is statistically significant.
AIM: To evaluate the correlation between the level of (18)F-fluoro-2-deoxyglucose ((18)F-FDG) uptake and glucose transporter 1 (GLUT1) expression in colorectal adenocarcinoma (CRA). METHODS: Forty four patients with resected CRA and preoperative (18)F-FDG positron emission tomography - computed tomography data were investigated in this study. Comparison of maximum standardized uptake value (SUVmax) of the lesion was made with GLUT1 expression by immunohistochemistry and various clinicopathologic factors including tumor volume, invasion depth, gross finding, and lymph node metastasis. RESULTS: SUVmax was 14.45 ± 7.0 in negative GLUT1 expression cases, 15.51 ± 5.7 in weak GLUT1 expression cases, and 16.52 ± 6.8 in strong GLUT1 expression cases, and there was no correlation between between GLUT1 expression and SUVmax. SUVmax was significantly correlated with tumor volume (P < 0.001). However, there was no significant differences in SUVmax and GLUT1 expression among other clinicopathologic factors. CONCLUSION:GLUT1 expression does not correlates significantly with (18)F-FDG uptake in CRA. (18)F-FDG uptake was increased with tumor volume, which is statistically significant.
Authors: T Yamamoto; Y Seino; H Fukumoto; G Koh; H Yano; N Inagaki; Y Yamada; K Inoue; T Manabe; H Imura Journal: Biochem Biophys Res Commun Date: 1990-07-16 Impact factor: 3.575
Authors: U Haberkorn; S I Ziegler; F Oberdorfer; H Trojan; D Haag; P Peschke; M R Berger; A Altmann; G van Kaick Journal: Nucl Med Biol Date: 1994-08 Impact factor: 2.408
Authors: M Findlay; H Young; D Cunningham; A Iveson; B Cronin; T Hickish; B Pratt; J Husband; M Flower; R Ott Journal: J Clin Oncol Date: 1996-03 Impact factor: 44.544
Authors: Claudio V Sole; Felipe A Calvo; Carlos Ferrer; Emilio Alvarez; Jose L Carreras; Enrique Ochoa Journal: Eur J Nucl Med Mol Imaging Date: 2014-10-01 Impact factor: 9.236
Authors: Ludwig G Strauss; Dirk Koczan; Sven Klippel; Leyun Pan; Stefan Willis; Christos Sachpekidis; Antonia Dimitrakopoulou-Strauss Journal: Am J Nucl Med Mol Imaging Date: 2013-09-19
Authors: Richard L Hesketh; Jiazheng Wang; Alan J Wright; David Y Lewis; Alice E Denton; Richard Grenfell; Jodi L Miller; Robert Bielik; Marcel Gehrung; Maria Fala; Susana Ros; Bangwen Xie; De-En Hu; Kevin M Brindle Journal: Cancer Res Date: 2019-05-14 Impact factor: 12.701
Authors: Ghada M K GabAllah; Mona Salah El-Din Habib; Shimaa El-Shafey Soliman; Zienab A Kasemy; Suzy F Gohar Journal: Saudi J Gastroenterol Date: 2017 Nov-Dec Impact factor: 2.485
Authors: Minjong Lee; Tae Sung Yeum; Ji Won Kim; Sohee Oh; Shin Ae Lee; Hong Ran Moon; Young Hoon Choi; Yoo Min Han; Ji Min Choi; Dong Kee Jang Journal: Gut Liver Date: 2014-05 Impact factor: 4.519